News and Announcements
Strong interim results of CAVATAK in Phase 2 Trial
- Published July 19, 2013 10:42AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
19 July 2013, Sydney, Australia: Viralytics Limited (ASX:VLA, OTC:VRACY) today announced strong interim results from its Phase 2 clinical trial of CAVATAK™ treatment in late stage melanoma patients.
The interim data shows solid progress towards achieving the primary endpoint of the study and stregthens the evidence of the tolerability of CAVATAK™ in late stage melanoma patients.
Earlier today, Dr Robert Andtbacka, the lead study investigator from the Huntsman Cancer Institute in the USA, presented on the safety and investigator assessed efficacy data from the first 35 patients in the CALM study at the 8th World Congress of Melanoma, Hamburg, Germany.
To read the full ASX announcement, please download the document below.
Company Updates
The Index Approach in Early-Stage Venture Capital: Reconsidered
The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]
The Future Is Now: The Evolution of Dealflow with Wholesale Investor
If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]
Investability of a Startup: A Comprehensive Guide for Angels and High-Net Worth Investors
Venturing into the Startup Scene Let’s dive into the intriguing world of startups. It’s a thrilling ride, isn’t it? Like finding a pearl in an ocean, spotting a promising startup amidst a sea of businesses is no easy task. This guide aims to light the way, focusing on the “The Investability of a Startup: 7 […]
Backed By Leading Investment Groups and Family Offices
